Showing results (1-10 of 692) with videos related to

Sort By:
Pageof 70
Biomolecules|January 28, 2026
Transcriptional Profiling Reveals Lineage-Specific Characteristics in ATR/CHK1 Inhibitor-Resistant Endometrial CancerTzu-Ting Huang, Jung-Min Lee
Cells|June 26, 2024
Combination Therapy Approach to Overcome the Resistance to PI3K Pathway Inhibitors in Gynecological CancersKristen R Ibanez, Tzu-Ting Huang, Jung-Min Lee
Pharmacological Research|March 8, 2022
Cell cycle checkpoints and beyond: Exploiting the ATR/CHK1/WEE1 pathway for the treatment of PARP inhibitor-resistant cancerNitasha Gupta, Tzu-Ting Huang, Sachi Horibata, et al.
Cancer Treatment Reviews|April 21, 2020
Targeting the PI3K pathway and DNA damage response as a therapeutic strategy in ovarian cancerTzu-Ting Huang, Erika J Lampert, Cynthia Coots, et al.
Cancers|April 14, 2026
Targeting ATR and PI3Kα Pathways Promotes Ferroptosis in <i>PIK3CA</i>-Wildtype Platinum-Resistant Endometrial CancerChi-Ting Shih, Kristen R Ibanez, Jung-Min Lee, et al.
Cells|December 10, 2025
The KIF18A Inhibitor ATX020 Induces Mitotic Arrest and DNA Damage in Chromosomally Instable High-Grade Serous Ovarian Cancer CellsJayakumar Nair, Tzu-Ting Huang, Maureen Lynes, et al.
Cells|November 27, 2024
Poly (ADP-Ribose) Polymerase Inhibitor Olaparib-Resistant <i>BRCA1</i>-Mutant Ovarian Cancer Cells Demonstrate Differential Sensitivity to PARP Inhibitor RechallengeChi-Ting Shih, Tzu-Ting Huang, Jayakumar R Nair, et al.
Oncogene|July 11, 2020
Resistance to the CHK1 inhibitor prexasertib involves functionally distinct CHK1 activities in BRCA wild-type ovarian cancerJayakumar Nair, Tzu-Ting Huang, Junko Murai, et al.
Cancer Research|January 19, 2024
AKT1 interacts with DHX9 to Mitigate R Loop-Induced Replication Stress in Ovarian CancerTzu-Ting Huang, Chih-Yuan Chiang, Jayakumar R Nair, et al.
The Journal of Nursing Research : JNR|June 25, 2005
Home environmental hazards among community-dwelling elderly persons in TaiwanTzu-Ting Huang
Pageof 70